New eczema drug HXN5003 enters first human safety trial
Symptom relief
Not yet recruiting
This early-stage study tests a new drug called HXN5003 in 28 healthy adults to see if it is safe and how the body processes it. The drug is being developed for atopic dermatitis (eczema). Participants receive either the drug or a placebo, and researchers monitor for side effects …
Phase: PHASE1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC